Vivo Bio Tech growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY25Mar 2025
+4.0%
−1.4%
−0.1%
+200.2%
+192.9%
+4.8%
+43.7%
−25.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VIVOBIOT₹13.98

Vivo Bio Tech Limited

· Pharma & Health
₹ CroreMcap ₹21.4 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
Revenue Growth—+4.0
EBITDA Growth—-1.4
EBIT Growth—-0.1
Net Income Growth—+200.2
EPS Growth—+192.9
Total Assets Growth—+4.8
Total Equity Growth—+43.7
Cash from Operations Growth—-25.3
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.